Developers of the Sputnik V coronavirus vaccine said Thursday that AstraZeneca should try combining its experimental COVID-19 vaccine with the Russian one to bolster efficacy, as reported in NASDAQ.
"If they go for a new clinical trial, we suggest trying a regimen of combining the AstraZeneca shot with the Sputnik V human adenoviral vector shot to boost efficacy," the developers posted on their Twitter account, adding that "combining vaccines may prove important for re-vaccinations."
Russia said interim data for the Sputnik V vaccine indicate that it is 92% effective at protecting people from COVID-19, while AstraZeneca reported that its COVID-19 canadidate was 70% effective in pivotal trials, and could be up to 90% effective.
Still, AstraZeneca is likely to run an additional global trial to assess the efficacy of its vaccine, its CEO Pascal Soriot was quoted as saying by Bloomberg, after questions were raised over the results from its late-stage study.
Meanwhile, when asked about these doubts, UK chief scientific adviser Patrick Vallance said the main point about the AstraZeneca vaccine was that it worked, "and that's very exciting."
To read more NewsPoints articles, click here.